about
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationA case report of hepatic veno-occlusive disease after ingesting daintiesPrevention and treatment of veno-occlusive disease.A toxicologist's guide to biomarkers of hepatic response.Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity.A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapyThe role of gemtuzumab ozogamicin in acute leukaemia therapy.The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.Pro-inflammatory and pro-coagulant properties of 6-thioguanine and 6-mercaptopurine: implications for their potential role in the development of sinusoidal obstruction syndrome.Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and...Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005.Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor.Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with beta-thalassemia.
P2860
Q28207989-53ED2789-3107-4C15-A862-542F495C725CQ34017832-D0261CC0-A0F4-486B-B5DD-09BC68138EB0Q34325854-5443E9A7-3DAC-4279-B3EA-EAD99CF36A6FQ34761550-9D51D42A-698C-4404-8D3F-22435A1EAE0BQ35758593-BAECF7B9-3C6B-4408-804B-02753E0BB910Q36059005-4899AA55-BB27-4001-81D7-55953749A507Q36367816-925F1C57-BBFA-4E91-8F79-E9B4F82CAE71Q36832124-D968E4F9-C89E-48A3-A6EB-3BFCD8A02A63Q38662393-5C36360B-E239-44FF-A77A-1A3ADEFA13EDQ40552183-F71BD6D0-47B7-40A4-B738-A2386B4779D3Q43249322-AA0E180A-8E9B-4BDA-B638-65E611CAFF78Q43848120-8421A003-AFD5-4916-8FB8-7A82919B2AD7Q46120171-53A45630-301B-440E-9E5B-559700743B2BQ46319967-A4121A39-182C-4A6E-B3BA-F1A445BDA3ECQ46468216-74836EB7-F789-44EF-A257-DC0B305EAC89Q46581528-5CE77922-5765-4CCB-A4B8-181AA538276B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Veno-occlusive disease of the liver.
@ast
Veno-occlusive disease of the liver.
@en
type
label
Veno-occlusive disease of the liver.
@ast
Veno-occlusive disease of the liver.
@en
prefLabel
Veno-occlusive disease of the liver.
@ast
Veno-occlusive disease of the liver.
@en
P1476
Veno-occlusive disease of the liver.
@en
P2093
Bearman SI
P304
P356
10.1097/00001622-200003000-00001
P577
2000-03-01T00:00:00Z